New Stem Cell Hope for Cirrhosis at Lecheng Maisel

This article provides a factual, objective overview of VUM02 therapy, including the clinical rationale behind it, the treatment pathway, and the practical aspects of accessing treatment at Lecheng Maisel. The information is drawn directly from the hospital’s official patient materials, the regulatory approval documentation, and peer‑reviewed studies, most notably the dose‑escalation trial led by Academician Wang Fusheng’s group, published in Signal Transduction and Targeted Therapy. Our aim is to present clear, actionable information without overstatement.

Cirrhosis is the end‑stage result of chronic liver injury caused by factors such as viral hepatitis, alcohol abuse, or metabolic disorders. In China, the annual incidence is approximately 17 per 100,000 population, and mortality rates among urban males aged 50–60 reach 112 deaths per 100,000. Once a patient progresses to decompensated cirrhosis—characterised by ascites, variceal bleeding, jaundice, or hepatic encephalopathy—the 5‑year survival rate falls to between 19% and 35%. Conventional treatments (antivirals, diuretics, endoscopic interventions) manage complications but do not reverse fibrosis or restore liver function. Liver transplantation remains the only curative option; however, donor shortages and high costs make it accessible to fewer than 1% of patients.

This context explains the considerable interest in regenerative approaches. Stem cell therapy, particularly with mesenchymal stromal cells (MSCs), has been investigated for over a decade, and the accumulated evidence now supports its potential to modulate inflammation, reduce fibrogenesis, and support endogenous hepatocyte regeneration.

VUM02 is a cryopreserved, off‑the‑shelf product manufactured from human umbilical cord tissue. Each infusion contains 1.5 × 10⁸ viable MSCs, and a complete course consists of three intravenous infusions administered one week apart. The product is manufactured under strict quality controls in a GMP‑compliant facility, ensuring batch‑to‑batch consistency.

The therapeutic effect is achieved through three interconnected mechanisms, as described in the hospital’s scientific literature:

It should be noted that VUM02 is not intended to replace the liver or to restore full function immediately. The goal is to slow disease progression, improve biochemical parameters, reduce complications, and potentially delay the need for transplantation.

The most robust clinical data supporting VUM02 come from the phase Ia/Ib dose‑escalation study by Wang Fusheng et al., published in 2024. This study enrolled 24 patients with decompensated cirrhosis and demonstrated acceptable safety (no serious adverse events attributable to the cells) and significant immunological changes consistent with reduced inflammation and improved liver function. Earlier meta‑analyses of MSC therapy for cirrhosis have reported overall improvement rates as high as 88.9%, although these figures are composite and should be interpreted with caution.

In the Lecheng Maisel program, real‑world monitoring is being conducted through structured follow‑up at 4, 8, and 12 weeks post‑treatment, with longer‑term tracking planned. The hospital has reported that most patients experience stable or improved Child‑Pugh scores and reduced requirements for ascites management, although specific aggregate data are still being collected.

To ensure safety and maximise benefit, VUM02 is indicated only for patients who meet strict criteria. These criteria are based on the regulatory approval and the hospital’s clinical protocol. The main inclusion and exclusion criteria are summarised below:

• Inclusion: Diagnosis of decompensated cirrhosis (Child‑Pugh class B or C); age 18–75 years; documented failure of standard medical therapy; willingness to comply with follow‑up.
• Exclusion: Hepatocellular carcinoma or other malignancy; severe cardiopulmonary disease; active infection; pregnancy; history of organ transplantation; significant encephalopathy; or uncontrolled comorbidities.

All candidates undergo a comprehensive pre‑treatment assessment at Lecheng Maisel, including laboratory tests, imaging, and a hepatology consultation, to confirm eligibility.

The treatment pathway is designed to be straightforward and patient‑friendly:

1. Remote consultation and record review – Patients submit medical history, imaging, and recent laboratory results for preliminary screening.
2. On‑site evaluation – A 1‑2 day outpatient workup at Lecheng Maisel, including blood tests, ultrasound, and specialist consultation.
3. Informed consent and scheduling – If eligible, the patient signs consent and receives a treatment calendar (three infusions, each separated by 7 days).
4. Infusion sessions – Each session lasts about 1 hour, with an additional 1‑hour observation period. No hospitalisation is required.
5. Post‑treatment monitoring – Follow‑up visits at 4, 8, and 12 weeks, with continued support via telemedicine.

From a service perspective, our team assists with travel arrangements, accommodation, translation, and appointment scheduling to ensure a seamless experience, particularly for patients travelling from other provinces or countries.

The pricing for VUM02 therapy has been publicly disclosed by Lecheng Maisel Hospital. Each infusion carries a fixed fee, and the full course is priced as follows:

This fee covers the cell product, medical procedures, and hospital services. It does not include travel, accommodation, or ancillary medications. The hospital offers detailed cost breakdowns during the consent process, and our service team can provide estimates for the total package.

VUM02 is approved conditionally by the Lecheng authorities as part of the “pilot zone” policy, which allows accelerated access to novel therapies while requiring ongoing real‑world data collection. The product has passed rigorous sterility, potency, and identity testing. To date, no tumour formation or severe immune reactions have been reported in treated patients, consistent with the established safety profile of umbilical cord‑derived MSCs.

It is essential to recognise that this is a supplemental therapy, not a substitute for standard care. Patients are advised to continue their prescribed medications (e.g., antiviral therapy, diuretics) and to maintain regular follow‑up with their hepatologist.